Abilify for kids: early safety trial shows promise
NCT ID NCT00102479
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested the safety and tolerability of aripiprazole (Abilify) in 21 children and adolescents aged 10 to 17 with schizophrenia or mania. Participants took daily doses of 2 to 30 mg for 14 days. The main goals were to see how many could tolerate the highest dose without side effects and to measure drug levels in the blood. This early-phase trial helps guide future dosing in younger patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aripiprazole (Abilify)
What this could lead to
If successful, this study could help doctors understand safe dosing of aripiprazole for young people with schizophrenia or bipolar disorder.
What could go wrong
This is a very small, early-phase study (21 participants) focused on safety, not on how well the drug works. Results may not apply to all children or guarantee effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.